Study analysis · Frontiers in Veterinary Science · 2023
The supplement most dog owners buy for arthritis just failed a gold-standard test—but a surprising shellfish extract outperformed a prescription drug.
A study of 75 dogs with hip arthritis found that green-lipped mussel and krill oil extracts improved weight-bearing just as much as the painkiller carprofen, while glucosamine/chondroitin did no better than placebo.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was a big fair test where dogs were split into groups by chance to get different treatments, like flipping a coin. Some dogs got special oils, some got medicine, and some got a fake pill. The dogs that got the real treatments could put more weight on their sore hips after a few weeks, but this was on dogs, so we can't know if it would work on people.
What’s the bottom line?
Scientists tested two fish-oil supplements, a common joint supplement, and an anti-inflammatory drug in dogs with hip arthritis. They measured how much dogs put weight on their sore leg before and after 6 weeks of treatment.
How strong is this study?
The researchers were very careful: they used a fake pill that looked the same, and nobody knew which dog got what, so it was fair. They also used a machine to measure how much weight dogs put on their legs, which is better than just guessing. However, it was a short study with only 15 dogs per group, so we should wait for more studies before being too sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
83 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 521 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This randomized controlled trial can establish causal relationships between the treatments and changes in peak vertical force (PVF) in dogs with hip osteoarthritis. However, it cannot establish causation for human arthritis, for long-term outcomes, or for subjective pain scores, which showed no significant change. The outcome is a surrogate (weight-bearing) rather than a direct measure of pain or quality of life, and the study duration was only 6 weeks.
Moderate COI
Moderate conflicts that may influence study outcomes
The study evaluates commercial products from several manufacturers, including PCSO-524 and EAB-277 from Pharmalink International Limited, which also manufactured the placebo. No explicit conflict of interest or funding statement is provided in the available text, raising concerns about undisclosed industry ties.
Conflict Details
Pharmalink International Limited: Manufacturer of PCSO-524 and EAB-277; manufactured the placebo capsules used in the study.
Nutramax Laboratories Consumer Care, Inc.: Manufacturer of Dasuquin, a glucosamine/chondroitin product tested in the study.
Zoetis: Manufacturer of Rimadyl (carprofen), a product tested in the study.
Barlean company: Supplier of soft gel capsule ingredients for the placebo.
Independent Analysis Safeguards
- Double-blinded design
- Block randomization
- Trial coordinator not involved in outcome assessment
- Placebo control
- Objective gait analysis using force plates
The provided text is truncated; a conflict of interest or funding statement may be present in the missing portion. The study's randomization and blinding procedures provide safeguards, but the industry involvement, particularly Pharmalink's role in manufacturing the placebo, warrants clarification regarding financial support and any influence on study conduct. No author affiliations or declarations are included in the visible text.
Key takeaways
- 01
Dogs given the fish-oil supplements (PCSO-524, EAB-277) or the drug carprofen put about 3–4.5% more weight on their sore leg after 4–6 weeks.
- 02
Dogs given a placebo or glucosamine/chondroitin did not improve.
- 03
The improvement was small but real and matched the effect of carprofen.
- 04
The joint supplement didn't do better than placebo in this 6-week test.
Surprising findings
- Subjective veterinarian orthopedic scores showed no significant changes, even when dogs objectively improved on the force plate.Veterinarians usually rely on physical exams to judge pain and lameness; this study shows those exams can miss objective improvements.
- Glucosamine/chondroitin, the most widely used joint supplement, performed no better than placebo in improving weight-bearing.This contradicts the widespread belief, promoted by many pet supplement brands, that glucosamine is effective for arthritis in dogs.
- The placebo group (sunflower oil) slightly worsened over 6 weeks (-0.33 %BW), indicating that without treatment, arthritis-related lameness is stable or progressive.Pet owners might assume some fluctuation is normal, but the placebo group's decline highlights that improvement is not spontaneous.
- EAB-277, a combination of krill oil phospholipids and green-lipped mussel lipids, was tested for the first time in OA dogs and matched carprofen's effect.It's rare for a novel nutraceutical to show efficacy comparable to a gold-standard NSAID in a randomized controlled trial on the first try.
Practical takeaways
If you're considering a nutraceutical for your dog's hip arthritis, ask your vet about marine lipid extracts like PCSO-524 (green-lipped mussel) or EAB-277 (mussel + krill) rather than glucosamine/chondroitin.
This is based on a single 6-week trial with small groups (14-16 dogs) and a published correction; consult your vet and monitor your dog's response.
medium confidenceDon't rely solely on glucosamine/chondroitin supplements for canine hip OA; this study suggests they may not provide noticeable improvements within 6 weeks.
The study only tested one formulation and duration; some dogs may still benefit, and longer-term studies have shown positive effects.
medium confidenceFor rapid pain relief in dogs with hip OA, carprofen is a proven NSAID that works within 2 weeks, but discuss risks with your vet, especially for dogs with kidney or GI issues.
Carprofen is a prescription drug with side effects; not all dogs can take NSAIDs.
high confidenceIf possible, ask for objective gait analysis (force plate) in research settings, or use home video of your dog running to track improvement, since physical exams may miss changes.
Force plate analysis isn't widely available in clinics; subjective owner and vet assessments can still be useful.
medium confidenceWhy this study matters
Nature's NSAID? Green-lipped mussel matches prescription drugs
In this 6-week randomized trial, dogs on PCSO-524 (green-lipped mussel extract) increased peak vertical force by 4.14 %BW, EAB-277 (krill + mussel blend) by 4.45 %BW, and carprofen by 4.21 %BW—all significantly better than placebo's -0.33 %BW.
Pet owners increasingly seek natural alternatives to NSAIDs, and this study suggests a marine lipid supplement could offer similar pain relief.
Glucosamine/chondroitin: another bust?
Dogs given glucosamine hydrochloride and chondroitin sulfate improved only 1.08 %BW, a change statistically indistinguishable from placebo. This popular supplement failed the objective force-plate test.
Millions of dog owners spend money on these supplements, but this study adds to mixed evidence and suggests they may not help in the short term.
Carprofen works fast but isn't the only option
Carprofen was the only treatment showing significant improvement at 2 weeks (3.14 %BW), but by week 6, the marine lipid groups caught up, suggesting a natural alternative may just need more time.
NSAIDs have side effects like GI ulcers; knowing a natural option works in 4-6 weeks could change treatment decisions.
Objective vs subjective: your vet's exam may miss real improvement
Force-plate analysis detected significant weight-bearing gains, but subjective orthopedic assessment scores (OAS) showed no significant change in any group, highlighting the limitation of human perception.
Many pet owners rely on vet 'good/bad' assessments; this shows why objective measurements matter and why subtle improvements can be invisible.
What does a 4% change in weight-bearing mean for your dog?
The authors note that while 5-10% changes are often cited as clinically significant, the 3.9-4.45 %BW improvement in this study was significantly better than placebo and had an effect size of 1.1, suggesting real benefit.
Numbers like '4%' sound small; contextualizing it as 'the equivalent of shifting 10-15 pounds of body weight onto the sore leg' makes it tangible.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two fish-oil supplements, a common joint supplement, and an anti-inflammatory drug in dogs with hip arthritis. They measured how much dogs put weight on their sore leg before and after 6 weeks of treatment.
Research results
Dogs given the fish-oil supplements (PCSO-524, EAB-277) or the drug carprofen put about 3–4.5% more weight on their sore leg after 4–6 weeks. Dogs given a placebo or glucosamine/chondroitin did not improve.
What this means - more context
The improvement was small but real and matched the effect of carprofen. The joint supplement didn't do better than placebo in this 6-week test.
To evaluate the effectiveness of glucosamine/chondroitin sulfate, marine-based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis in a prospective, block-randomized, double-blinded, placebo-controlled clinical trial.
In 75 dogs with hip osteoarthritis, treatment with PCSO-524, EAB-277, or carprofen for 4–6 weeks significantly improved weight-bearing (peak vertical force, PVF) compared to baseline and compared to placebo (mean increases 3.90–4.45 %BW at week 6). Glucosamine/chondroitin sulfate did not produce significant improvement over placebo. Subjective orthopedic assessment scores showed no significant changes in any group. This study has a published correction/erratum; readers should consult the correction notice for updated information.
Methods Used
Prospective, block-randomized, double-blinded, placebo-controlled trial. 75 client-owned dogs with hip OA were randomized to PCSO-524 (5 mg/kg/day), glucosamine HCl + chondroitin sulfate (~30 mg/kg/day), EAB-277 (5 mg/kg/day), carprofen (4.4 mg/kg/day), or placebo (sunflower oil). Peak vertical force (PVF) via force plate gait analysis and subjective orthopedic assessment scores (OAS) were measured at baseline, weeks 2, 4, and 6.
Main Finding
PCSO-524, EAB-277, and carprofen significantly increased PVF from baseline at weeks 4 and 6, with mean changes of 3.90–4.45 %BW, significantly greater than placebo (0.08 to −0.33 %BW) and glucosamine/chondroitin. Glucosamine/chondroitin showed no significant difference from placebo. Subjective OAS did not change significantly in any group.
Confidence Level
Relatively high for an RCT with double-blinding and placebo control, but limited by small group sizes (14–16 dogs), short follow-up (6 weeks), and the existence of a published corrigendum. Subjective OAS were not validated and failed to detect changes.
Study Flags
Red Flags
- •Published corrigendum/erratum (10.3389/fvets.2023.1252778) - results may have been corrected
- •Small sample size per group (14-16 dogs)
- •Subjective veterinary orthopedic scores showed no significant treatment effect
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Subjective veterinarian orthopedic scores showed no significant changes, even when dogs objectively improved on the force plate.
Veterinarians usually rely on physical exams to judge pain and lameness; this study shows those exams can miss objective improvements.
Practical Takeaways
If you're considering a nutraceutical for your dog's hip arthritis, ask your vet about marine lipid extracts like PCSO-524 (green-lipped mussel) or EAB-277 (mussel + krill) rather than glucosamine/chondroitin.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 521 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study was a big fair test where dogs were split into groups by chance to get different treatments, like flipping a coin. Some dogs got special oils, some got medicine, and some got a fake pill. The dogs that got the real treatments could put more weight on their sore hips after a few weeks, but this was on dogs, so we can't know if it would work on people.
Moderate conflicts detected — such as industry funding with partial involvement. A meaningful penalty has been applied.
Strengths
- Prospective randomized controlled design
- Double-blinded (investigators and owners)
- Placebo control and positive control (carprofen)
Weaknesses
- Animal model, not human
- Primary outcome (PVF) is a surrogate measure, not directly clinical pain
- Subjective OAS not validated and showed no significant findings
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists tested two fish-oil supplements, a common joint supplement, and an anti-inflammatory drug in dogs with hip arthritis. They measured how much dogs put weight on their sore leg before and after 6 weeks of treatment.
Research results
Dogs given the fish-oil supplements (PCSO-524, EAB-277) or the drug carprofen put about 3–4.5% more weight on their sore leg after 4–6 weeks. Dogs given a placebo or glucosamine/chondroitin did not improve.
What this means - more context
The improvement was small but real and matched the effect of carprofen. The joint supplement didn't do better than placebo in this 6-week test.
To evaluate the effectiveness of glucosamine/chondroitin sulfate, marine-based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis in a prospective, block-randomized, double-blinded, placebo-controlled clinical trial.
In 75 dogs with hip osteoarthritis, treatment with PCSO-524, EAB-277, or carprofen for 4–6 weeks significantly improved weight-bearing (peak vertical force, PVF) compared to baseline and compared to placebo (mean increases 3.90–4.45 %BW at week 6). Glucosamine/chondroitin sulfate did not produce significant improvement over placebo. Subjective orthopedic assessment scores showed no significant changes in any group. This study has a published correction/erratum; readers should consult the correction notice for updated information.
Methods Used
Prospective, block-randomized, double-blinded, placebo-controlled trial. 75 client-owned dogs with hip OA were randomized to PCSO-524 (5 mg/kg/day), glucosamine HCl + chondroitin sulfate (~30 mg/kg/day), EAB-277 (5 mg/kg/day), carprofen (4.4 mg/kg/day), or placebo (sunflower oil). Peak vertical force (PVF) via force plate gait analysis and subjective orthopedic assessment scores (OAS) were measured at baseline, weeks 2, 4, and 6.
Main Finding
PCSO-524, EAB-277, and carprofen significantly increased PVF from baseline at weeks 4 and 6, with mean changes of 3.90–4.45 %BW, significantly greater than placebo (0.08 to −0.33 %BW) and glucosamine/chondroitin. Glucosamine/chondroitin showed no significant difference from placebo. Subjective OAS did not change significantly in any group.
Confidence Level
Relatively high for an RCT with double-blinding and placebo control, but limited by small group sizes (14–16 dogs), short follow-up (6 weeks), and the existence of a published corrigendum. Subjective OAS were not validated and failed to detect changes.
Study Flags
Red Flags
- •Published corrigendum/erratum (10.3389/fvets.2023.1252778) - results may have been corrected
- •Small sample size per group (14-16 dogs)
- •Subjective veterinary orthopedic scores showed no significant treatment effect
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Subjective veterinarian orthopedic scores showed no significant changes, even when dogs objectively improved on the force plate.
Veterinarians usually rely on physical exams to judge pain and lameness; this study shows those exams can miss objective improvements.
Practical Takeaways
If you're considering a nutraceutical for your dog's hip arthritis, ask your vet about marine lipid extracts like PCSO-524 (green-lipped mussel) or EAB-277 (mussel + krill) rather than glucosamine/chondroitin.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 521 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Animal RCT
Subject
Lower probability
on the GRADE evidence scale
This study was a big fair test where dogs were split into groups by chance to get different treatments, like flipping a coin. Some dogs got special oils, some got medicine, and some got a fake pill. The dogs that got the real treatments could put more weight on their sore hips after a few weeks, but this was on dogs, so we can't know if it would work on people.
Moderate conflicts detected — such as industry funding with partial involvement. A meaningful penalty has been applied.
Strengths
- Prospective randomized controlled design
- Double-blinded (investigators and owners)
- Placebo control and positive control (carprofen)
Weaknesses
- Animal model, not human
- Primary outcome (PVF) is a surrogate measure, not directly clinical pain
- Subjective OAS not validated and showed no significant findings
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers were very careful: they used a fake pill that looked the same, and nobody knew which dog got what, so it was fair. They also used a machine to measure how much weight dogs put on their legs, which is better than just guessing. However, it was a short study with only 15 dogs per group, so we should wait for more studies before being too sure.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
83 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=75)+6.3/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 521 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. This randomized controlled trial can establish causal relationships between the treatments and changes in peak vertical force (PVF) in dogs with hip osteoarthritis. However, it cannot establish causation for human arthritis, for long-term outcomes, or for subjective pain scores, which showed no significant change. The outcome is a surrogate (weight-bearing) rather than a direct measure of pain or quality of life, and the study duration was only 6 weeks.
Moderate COI
Moderate conflicts that may influence study outcomes
The study evaluates commercial products from several manufacturers, including PCSO-524 and EAB-277 from Pharmalink International Limited, which also manufactured the placebo. No explicit conflict of interest or funding statement is provided in the available text, raising concerns about undisclosed industry ties.
Conflict Details
Pharmalink International Limited: Manufacturer of PCSO-524 and EAB-277; manufactured the placebo capsules used in the study.
Nutramax Laboratories Consumer Care, Inc.: Manufacturer of Dasuquin, a glucosamine/chondroitin product tested in the study.
Zoetis: Manufacturer of Rimadyl (carprofen), a product tested in the study.
Barlean company: Supplier of soft gel capsule ingredients for the placebo.
Independent Analysis Safeguards
- Double-blinded design
- Block randomization
- Trial coordinator not involved in outcome assessment
- Placebo control
- Objective gait analysis using force plates
The provided text is truncated; a conflict of interest or funding statement may be present in the missing portion. The study's randomization and blinding procedures provide safeguards, but the industry involvement, particularly Pharmalink's role in manufacturing the placebo, warrants clarification regarding financial support and any influence on study conduct. No author affiliations or declarations are included in the visible text.